All News

A new blood test can detect the abnormal pattern of chemical alteration of DNA associated with bladder cancer, suggesting it may be possible to assess susceptibility to the disease, say researchers from Brown University, Providence, RI.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase II, III, and IV overactive bladder trials that are currently recruiting participants as well as phase II BPH trials. This list is current as of Feb. 16, 2011.

Urology drugs and devices that are in the pipeline from Exelixis, Inc., ADVENTRX Pharmaceuticals, Viking Systems, Inc., Epigenomics AG, and Predictive Biosciences.

If we are to accurately assess the potential advantages or disadvantages of any new technique or treatment, we must apply rigorous scientific standards and use validated instruments with comparisons to the contemporary gold standard.

The newest urology products and services from Endo Pharmaceuticals, UroMed, Hunter House Publishers, and Women Against Prostate Cancer.